



SHREE SAHKAR EDUCATION TRUST


DHANVANTARY INSTITUTE OF PHARMACY AND RESEARCH



IGNITING KNOWLEDGE • ACCELERATING RESEARCH • INSPIRING INNOVATION

JULY 2026 TO DECEMBER 2026

About DIPR




Welcome to the inaugural issue of The Catalyst, the official e-bulletin of the Dhanvantary Institute of Pharmacy and Research (DIPR) in Kim, Gujarat. As we commence our premier 2026–2027 academic session under the revised PCI and NEP 2020 guidelines, DIPR stands committed to fostering excellence in pharmaceutical sciences. The Catalyst embodies our vision to ignite intellectual curiosity and accelerate innovation. Through this publication, we aim to bridge foundational academic concepts with cutting-edge industry advancements, showcasing the collective dedication of our students, faculty, and research divisions.






Editorial Desk



Message from the Chief Editor Welcome to the very first edition of The Catalyst. The landscape of pharmaceutical sciences is evolving at an unprecedented pace. Today, the convergence of computational drug design, molecular docking, and formulation science is redefining how we approach therapeutic development. From exploring quantitative structure-activity relationships to pioneering green synthesis methods for biopolymers and nanocomposites, our focus must remain on sustainable, high-impact research.

This e-bulletin is designed to be a dynamic forum for our campus community. It will capture the spirit of our laboratories and classrooms, translating our daily academic rigor into a shared narrative of progress. I encourage all students and faculty to engage deeply with the articles, celebrate our institutional milestones, and draw inspiration from the rapid transformations occurring in the global pharma sector. Let this publication be the spark that drives your next research inquiry.

— Dr. Uttam Ashok More, Principal & Professor of Pharmaceutical Chemistry






Featured Article




Institutional News



Achievements:



Pharma Reports (Research Lab)



AI-Driven Drug Discovery: Artificial intelligence is rapidly transitioning into an essential capability, accelerating early-stage drug discovery by analyzing massive datasets to predict drug efficacy and minimize trial-and-error processes. AI platforms have also been successfully utilized to formulate affordable, serum-free T cell expansion media, drastically reducing costs.

Metabolic Therapeutics Revolution: A major paradigm shift is underway with non-peptide oral GLP-1 receptor agonists, notably Eli Lilly's orforglipron, targeting obesity and Type 2 diabetes. This oral format bypasses the need for cold-chain storage and offers a highly anticipated alternative to standard injectable therapies.

Green Synthesis & Thermostable Delivery: Researchers have introduced breakthrough thermostable vaccine formulations that encapsulate components within a biodegradable nanocellulose matrix. This scalable, green lyophilized powder maintains vaccine potency at temperatures up to 40°C, virtually eliminating the global reliance on cold-chain infrastructure.

Novel Oncology Approvals: The regulatory landscape saw significant targeted oncology approvals in late summer 2026, including zidesamtinib for metastatic ROS1-positive non-small cell lung cancer, and daraxonrasib for metastatic pancreatic cancer.